niacinamide has been researched along with ci 1044 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auclair, E; Avenel, N; Bertin, B; Bigot, C; Burnouf, C; Calvet, A; Chan, K; Doherty, AM; Durand, C; Fasquelle, V; Féru, F; Gilbertsen, R; Jacobelli, H; Kebsi, A; Lallier, E; Maignel, J; Martin, B; Milano, S; Ouagued, M; Pascal, Y; Pruniaux, MP; Puaud, J; Rocher, MN; Terrasse, C; Wrigglesworth, R | 1 |
| Astier, A; Bertrand, C; Jacob, C; Lagente, V; Martin-Chouly, CA; Pruniaux, MP | 1 |
| Belleguic, C; Bertrand, C; Brinchault, G; Depincé, A; Lagente, V; Leportier-Comoy, C; Martin-Chouly, CA; Ouagued, M; Pruniaux, MP | 1 |
| Chevalier, S; Daguès, N; Freslon, JL; Guigon, G; Hanton, G; Ledieu, D; Pawlowski, V; Sobry, C | 1 |
| Borde, F; Chevalier, S; Daguès, N; Freslon, JL; Hanton, G; Pawlowski, V; Sobry, C; Soler, S | 1 |
| Stachlewitz, RF | 1 |
| Chevalier, S; Comby, P; Daguès, N; Hanton, G; Le Net, JL; Provost, JP; Sobry, C | 1 |
| Brunet, C; Chevalier, S; Freslon, JL; Korkmaz, S; Maupoil, V; Sobry, C | 1 |
| Bertin, B; Bertrand, CP; Bouget, A; Burnouf, C; Doherty, AM; Dubuit, JP; Julien-Larose, C; Lagente, V; Leportier, C; Martin, B; Moreau, F; Ouaged, M; Pruniaux, MP; Rocher, MN | 1 |
| Enerson, BE; Lawton, MP; Peters, D; Sheth, CM; Weaver, JL | 1 |
| Bougnoux, P; Chantôme, A; Chevalier, S; Clarysse, L; Guéguinou, M; Potier-Cartereau, M; Vandecasteele, G; Vandier, C | 1 |
| Conte, T; Deeley, B; Enerson, BE; Joseph, EC; Kreeger, JM; Lawton, MP; Nugent, P; Obert, LA; Portugal, S; Rief, C; Sokolowski, SA; Swanson, TA; Wisialowski, TA | 1 |
| Bancos, S; Enerson, BE; González, C; Goodwin, D; Knapton, A; Lawton, MP; Stewart, S; Tobin, GA; Weaver, JL; Xu, L; Zhang, J; Zhang, L | 1 |
1 trial(s) available for niacinamide and ci 1044
| Article | Year |
|---|---|
The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Azepines; Carboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dexamethasone; Dose-Response Relationship, Drug; Female; France; Humans; Male; Middle Aged; Niacinamide; Nitriles; Phosphodiesterase Inhibitors; Polysaccharides, Bacterial; Pulmonary Disease, Chronic Obstructive; Rolipram; Tumor Necrosis Factor-alpha | 2005 |
12 other study(ies) available for niacinamide and ci 1044
| Article | Year |
|---|---|
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Azepines; Binding, Competitive; Brain; Bronchoalveolar Lavage; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Eosinophils; Ferrets; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Isoenzymes; Male; Monocytes; Niacinamide; Ovalbumin; Phosphodiesterase I; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Radioligand Assay; Rats; Rats, Wistar; Structure-Activity Relationship; Trachea; Tumor Necrosis Factor-alpha; Vomiting | 2000 |
Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Azepines; Blotting, Western; Bronchodilator Agents; Carboxylic Acids; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Therapy, Combination; Fibroblasts; Humans; Isoenzymes; Lung; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metalloproteases; Niacinamide; Nitriles; Phosphodiesterase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rolipram; Tetradecanoylphorbol Acetate; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2004 |
Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Azepines; Cluster Analysis; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Fibrinogen; Gene Expression Profiling; Gene Expression Regulation; Inflammation; Interleukins; Male; Mesenteric Arteries; Mesentery; Niacinamide; Oligonucleotide Array Sequence Analysis; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2007 |
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
Topics: Animals; Azepines; Biomarkers, Pharmacological; Cell Adhesion Molecules; Cluster Analysis; Cytokines; Enzymes; Gene Expression Profiling; Male; Mesenteric Arteries; Niacinamide; Oligonucleotide Array Sequence Analysis; Peripheral Vascular Diseases; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Up-Regulation | 2007 |
Bringing biomarkers to the masses: an elegant approach to discover potential biomarkers of vascular injury.
Topics: Animals; Azepines; Biomarkers, Pharmacological; Cell Adhesion Molecules; Cluster Analysis; Cytokines; Enzymes; Gene Expression Profiling; Humans; Mesenteric Arteries; Niacinamide; Oligonucleotide Array Sequence Analysis; Peripheral Vascular Diseases; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rats; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; RNA, Messenger; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Up-Regulation | 2007 |
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog.
Topics: Acute-Phase Reaction; Administration, Oral; Animals; Azepines; Blood Vessels; C-Reactive Protein; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Male; Necrosis; Niacinamide; Phosphodiesterase 4 Inhibitors; Recovery of Function; Serum Amyloid A Protein; Toxicity Tests; Withholding Treatment | 2008 |
An increased regional blood flow precedes mesenteric inflammation in rats treated by a phosphodiesterase 4 inhibitor.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Analysis of Variance; Animals; Azepines; Blood Pressure; Cardiac Output; Duodenum; Heart; Hemodynamics; Ileum; Inflammation; Jejunum; Male; Mesenteric Arteries; Muscle, Skeletal; Necrosis; Niacinamide; Norepinephrine; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Splanchnic Circulation | 2009 |
Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Topics: Administration, Oral; Animals; Azepines; Carboxylic Acids; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Inflammation; Inhibitory Concentration 50; Lipopolysaccharides; Male; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Eosinophilia; Rats; Rats, Inbred BN; Rolipram; Tumor Necrosis Factor-alpha | 2010 |
Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in Sprague-Dawley rats.
Topics: Animals; Azepines; Biomarkers; Dose-Response Relationship, Drug; Enzyme Inhibitors; Immunohistochemistry; Male; Mesenteric Arteries; Molsidomine; NG-Nitroarginine Methyl Ester; Niacinamide; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Phosphodiesterase 4 Inhibitors; Rats; Rats, Sprague-Dawley; Tyrosine; Vascular System Injuries | 2011 |
cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex.
Topics: Adrenergic beta-Agonists; Azepines; Calcium; Calcium Channels; Carbazoles; Cell Line, Tumor; Cell Movement; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; HEK293 Cells; Humans; Isoproterenol; Membrane Microdomains; Niacinamide; ORAI1 Protein; Phosphodiesterase 4 Inhibitors; Protein Binding; Protein Kinase Inhibitors; Pyrroles; Small-Conductance Calcium-Activated Potassium Channels | 2014 |
Hemodynamic correlates of drug-induced vascular injury in the rat using high-frequency ultrasound imaging.
Topics: Animals; Azepines; Drug-Related Side Effects and Adverse Reactions; Fenoldopam; Hemodynamics; Male; Mesenteric Arteries; Niacinamide; Pyridazines; Pyridines; Rats; Rats, Sprague-Dawley; Ultrasonography; Vascular System Injuries | 2014 |
The role of eNOS phosphorylation in causing drug-induced vascular injury.
Topics: Adenosine; Animals; Aorta; Azepines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Male; Niacinamide; Nitric Oxide; Nitric Oxide Synthase Type III; Nitrites; Phosphorylation; Rats; Rats, Sprague-Dawley; Vascular System Injuries | 2014 |